07:44 AM EDT, 06/06/2025 (MT Newswires) -- Arvinas ( ARVN ) and Pfizer ( PFE ) submitted a new drug application to the US Food and Drug Administration for vepdegestrant as a treatment for patients with ESR1-mutated advanced or metastatic breast cancer, according to a Friday statement from Arvinas ( ARVN ).

The company said the application was based on the results of a phase 3 trial that evaluated vepdegestrant in comparison with fulvestrant. The trial's primary endpoint was progression-free survival and the key secondary endpoint is overall survival, Arvinas ( ARVN ) added.

Shares of Arvinas ( ARVN ) were up more than 1% in recent premarket activity Friday.

Price: 7.00, Change: +0.08, Percent Change: +1.16